Nonalcoholic fatty liver disease (NAFLD), a chronic liver disease in children, ranges from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). We investigated the role of Angiopoietin-2 (Ang-2) as a biomarker for pediatric NAFLD-related liver damage.
We assessed the plasma levels of Ang-2 and cytokeratin-18 (CK18) fragments and their association with histologic activity in 76 children with NAFLD and 28 controls.
The mean plasma levels of Ang-2 and CK18 were higher in children with NAFLD than in age-matched controls (Ang-2 155.4 ± 72.5 vs 7.5 ± 2.3 ng/mL, p < 0.001; CK18 390.4 ± 145.6 vs 193.9 ± 30.8 IU/L, p < 0.001). Ang-2 was significantly increased (p < 0.0001) in children with NASH (N = 41) while CK18 was significantly increased (p = 0.002) in children with fibrosis (N = 47). Ang-2 levels accurately predicted NASH (AUROC 0.911; 95% CI 0.844–0.979; p < 0.0001), while CK18 predicted both NASH (AUROC 0.827; 95% CI 0.735–0.919; p < 0.0001) and fibrosis (AUROC 0.724; 95% CI 0.611–0.837; p = 0.001). Ang-2 and CK18 in combination were good predictors of NASH with a sensitivity of 71.4% and a specificity of 100%.
In conclusion, our data suggested Ang-2 as a suitable biomarker of NASH in the pediatric population. However, our findings need external validation in other cohorts.
Several circulating factors have been extensively studied as potential biomarkers for NASH.
Angiopoietin-2 circulating levels are increased in children with NAFLD and are associated with NASH.
Angiopoietin-2 levels are more efficient than CK18 levels at assessing the most severe form of disease, and the combining of these two biomarkers reached a positive predictive value of 100% for NASH.
This is a preview of subscription content, access via your institution
Subscribe to Journal
Get full journal access for 1 year
only $9.15 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Younossi, Z. M. Non-alcoholic fatty liver disease—a global public health perspective. J. Hepatol. 70, 531–544 (2019).
Nobili, V. et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat. Rev. Gastroenterol. Hepatol. 16, 517–530 (2019).
Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).
Ballestri, S. et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J. Gastroenterol. Hepatol. 31, 936–944 (2016).
Marra, F. & Svegliati-Baroni, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J. Hepatol. 68, 280–295 (2018).
Povero, D. & Feldstein, A. E. Novel molecular mechanisms in the development of non-alcoholic steatohepatitis. Diabetes Metab. J. 40, 1–11 (2016).
Gehrke, N. & Schattenberg, J. M. Metabolic inflammation—a role for hepatic inflammatory pathways as driver of comorbidities in non-alcoholic fatty liver disease (NAFLD)? Gastroenterology 158, 1929–1947 (2020).
Hammoutene, A. & Rautou, P. E. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J. Hepatol. 70, 1278–1291 (2019).
Lefere, S. et al. Angiopoietin-2 promotes pathological angiogenesis and is a novel therapeutic target in murine non-alcoholic fatty liver disease. Hepatology 69, 1087–1104 (2019).
Pauta, M. et al. Overexpression of angiopoietin-2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition. Liver. Int. 35, 1383–1392 (2015).
Mosca, A., Panera, N., Crudele, A. & Alisi, A. Noninvasive diagnostic tools for pediatric NAFLD: where are we now? Expert. Rev. Gastroenterol. Hepatol. 14, 1035–1046 (2020).
Vajro, P. et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J. Pediatr. Gastroenterol. Nutr. 54, 700–713 (2012).
Farpour-Lambert, N. J. et al. Childhood obesity is a chronic disease demanding specific health care–a position statement from the Childhood Obesity Task Force (COTF) of the European Association for the Study of Obesity (EASO). Obes. Facts 8, 342–349 (2015).
Cacciari, E. et al. Italian cross-sectional growth charts for height, weight and BMI (2 to 20 yr). J. Endocrinol. Invest. 29, 581–593 (2006).
Matsuda, M. & DeFronzo, R. A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470 (1999).
Štěpánek, L. et al. Associations between homeostasis model assessment (HOMA) and routinely examined parameters in individuals with metabolic syndrome. Physiol. Res. 68, 921–930 (2019).
Flynn, J. T. et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 140, e20171904 (2017).
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 128 (Suppl. 5), S213–S256 (2011).
Brunt, E. M. et al. Portal chronic inflammation in non-alcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-clinicopathologic correlations from the non-alcoholic steatohepatitis clinical research network. Hepatology 49, 809–820 (2009).
Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313–1321 (2005).
Akwii, R. G., Sajib, M. S., Zahra, F. T. & Mikelis, C. M. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells 8, 471 (2019).
Voigtländer, T. et al. Angiopoietin-2 and biliary diseases: elevated serum, but not bile levels are associated with cholangiocarcinoma. PLoS ONE 9, e97046 (2014).
Hernández-Bartolomé, Á. et al. Angiopoietin-2/angiopoietin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. World J. Gastroenterol. 22, 9744–9751 (2016).
Schuldt, E. A. et al. Circulating angiopoietin-2 and its soluble receptor Tie-2 concentrations are related to inflammatory markers in the general population. Cytokine 105, 1–7 (2018).
Huang, H., Bhat, A., Woodnutt, G. & Lappe, R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat. Rev. Cancer 10, 575–585 (2010).
Abdel-Salam, M. et al. Evaluation of angiopoietin-2 serum level as a marker of cardiovascular risk in children with chronic kidney disease. Open J. Nephrol. 5, 105–116 (2015).
Wang, K. et al. Angiopoietin-1, angiopoietin-2 and bicarbonate as diagnostic biomarkers in children with severe sepsis. PLoS ONE 9, e108461 (2014).
Ricciuto, D. R. et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit. Care. Med. 39, 702–710 (2011).
Zonneveld, R. et al. Low serum Angiopoietin-1, high serum Angiopoietin-2, and high Ang-2/Ang-1 protein ratio are associated with early onset sepsis in Surinamese newborns. Shock 48, 638–643 (2017).
Coulon, S. et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 59, 442–449 (2012).
Coulon, S. et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 57, 1793–1805 (2013).
Miyao, M. et al. Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression. Lab. Invest. 95, 1130–1144 (2015).
Wang, R., Huebert, R. C. & Shah, V. H. Sinusoidal endothelial cells coordinate liver regeneration and angiogenesis via angiopoietin-2: an ode to prometheus. Gastroenterology 147, 533–534 (2014).
Hernández-Bartolomé, A. et al. Angiopoietin-2 serum levels improve noninvasive fibrosis staging in chronic hepatitis C: a fibrogenic-angiogenic link. PLoS ONE 8, e66143 (2013).
Makhlouf, M. M. et al. Serum angiopoietin-2 as a noninvasive diagnostic marker of stages of liver fibrosis in chronic hepatitis C patients. Egypt. J. Intern. Med. 28, 140–148 (2016).
Feldstein, A. E. et al. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50, 1072–1078 (2009).
Lee, J. et al. Accuracy of cytokeratin 18 (M30 and M65) in detecting non-alcoholic steatohepatitis and fibrosis: a systematic review and meta-analysis. PLoS ONE 15, e0238717 (2020).
Mandelia, C. et al. Plasma cytokeratin-18 level as a novel biomarker for liver fibrosis in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr. 63, 181–187 (2016).
The authors would like to thank our nursing staff members (Giulia Pace, Anna Maria Conti, and Loriana Giammaria) for their precious assistance in caring patients and in recruiting them for this project.
This work was supported by Italian Ministry of Health (Fondi-di-Ricerca Corrente 2020) to A.A.
The authors declare no competing interests.
The consent was obtained for biobanking of anonymized samples and use in future investigations relating to the same topic.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Manco, M., Panera, N., Crudele, A. et al. Angiopoietin-2 levels correlates with disease activity in children with nonalcoholic fatty liver disease. Pediatr Res 91, 1781–1786 (2022). https://doi.org/10.1038/s41390-021-01666-5